Communicate with Supplier? Supplier
Kelly Ms. Kelly
What can I do for you?
+8613375313165
Chat Now
Chat Now Contact Supplier

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsActive Pharmaceutical Ingredient(API)Vemurafenib API

Vemurafenib API (Total 3 Products)

Product categories of Vemurafenib API, we are specialized manufacturers from China, Vemurafenib Api, Vemurafenib Cas 1029872-54-5 suppliers/factory, wholesale high-quality products of Vemurafenib Api Cas 1029872-54-5 R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Top Quality Best Price Cas 1029872-54-5

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 1R 1 4 Hydroxy 3 1R 6 methoxy 1 4 methoxybenzyl 2 methyl 1 2 3 4 tetrahydro 7 isoquinolinyl oxy benzyl 6 methoxy 2 methy l 1 2 3 4 tetrahydro 7 isoquinolinol N 3 5 4 chlorophenyl 1H pyrrolo 2 3 b pyridin 3 yl carbonyl 2 4 difluorophenyl...
Pharmaceutical Raw Material Cas 1029872-54-5

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 1R 1 4 Hydroxy 3 1R 6 methoxy 1 4 methoxybenzyl 2 methyl 1 2 3 4 tetrahydro 7 isoquinolinyl oxy benzyl 6 methoxy 2 methy l 1 2 3 4 tetrahydro 7 isoquinolinol N 3 5 4 chlorophenyl 1H pyrrolo 2 3 b pyridin 3 yl carbonyl 2 4 difluorophenyl...
Vemurafenib API Cas 1029872-54-5

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 1R 1 4 Hydroxy 3 1R 6 methoxy 1 4 methoxybenzyl 2 methyl 1 2 3 4 tetrahydro 7 isoquinolinyl oxy benzyl 6 methoxy 2 methy l 1 2 3 4 tetrahydro 7 isoquinolinol N 3 5 4 chlorophenyl 1H pyrrolo 2 3 b pyridin 3 yl carbonyl 2 4 difluorophenyl...

China Vemurafenib API Suppliers

Vemurafenib is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.

Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.

Home

Product

Whatsapp

About Us

Inquiry